A. Carfilzomib, pomalidomide, dexamethasone B. Isatuximab, carfilzomib, dexamethasone C. Daratumumab, carfilzomib, dexamethasone D. Dexamethasone, pomalidomide, daratumumab

A. ≥2 prior lines of therapy B. Refractory to an immunomodulatory drug (IMiD) or proteasome inhibitor (PI) C. Refractory or intolerant to an anti-CD38 agent D. Eastern Cooperative Oncology Group Performance Score (ECOG PS) 0-2

A. Immune effector cell neurotoxicity syndrome (ICANS) B. Cytokine release syndrome (CRS) C. Keratopathy D. Cytopenias

A. Dexamethasone 10 mg IV every 12-24 hours for 2-3 days B. Dexamethasone 20 mg IV every 12 hours C. Dexamethasone 10-20 mg IV every 6 hours D. Dexamethasone 20 mg IV every 12 hours

A. About 70% of cases are symptomatic B. It is irreversible C. It develops late during treatment D. Prophylaxis consists of preservative-free lubricant eye drops 4-8 times per day, and patients are advised not to wear contact lenses

A. Pause infusion, provide supportive care, continue at the full rate until resolution to grade ≤1 B. Discontinue until resolution to grade ≤1; extend infusion time, mandate pre-medications C. Pause infusion, provide supportive care, continue at half the original rate until resolution to grade ≤1 D. Discontinue until resolution to grade ≤1; shorten infusion time, mandate pre-medications

A. Ophthalmology B. Neurology C. Dermatology D. Pulmonology